Left Lane Capital targets high-growth internet and consumer technology businesses that drive the digitization of the real economy and foster enduring, long-term customer relationships.
About Left Lane Capital
Left Lane Capital is a New York-based growth-equity firm that has built a focused practice around consumer-facing internet and software companies, with a portfolio that has tilted heavily toward marketplaces, DTC, fintech, and consumer health and wellness. The firm’s healthcare exposure is real and growing, with portfolio companies including Talkiatry (behavioral health), Evvy (vaginal microbiome diagnostics and care), Mindspan (memory care and cognitive assessment), Moka.care (workplace mental wellness), Everlab (AI-powered preventive care), and Good Health Company (DTC men’s and women’s health), and an investment in AnswersNow (a Series B autism therapy platform). The pattern across these deals is consistent: Left Lane is a consumer health investor more than a clinical health investor, and the wedge it looks for is a consumer-acquisition motion, a defensible product experience, and unit economics that work at scale. Stage focus is growth-stage, generally Series B and beyond, with check sizes in the twenty-to-eighty-million range and a willingness to lead larger rounds for breakout companies. The firm is not a seed or Series A lead, although it occasionally does smaller checks where it has been tracking a company for years. Geography is global with a US tilt and meaningful European activity, particularly in France and the UK; the New York office is the firm’s center of gravity. Founders who should approach Left Lane are growth-stage consumer health, DTC health, virtual care, and consumer wellness founders with strong unit economics, a defensible brand, and the ability to scale a paid-acquisition or organic-growth motion across markets. Founders should also approach Left Lane if they are running a tech-enabled services business in healthcare with consumer-grade experience and growth-equity-grade financials. Founders who should look elsewhere are early-stage seed and Series A founders, clinical-stage biotech founders, devices founders, and pure B2B health-IT founders selling to health systems; this is not Left Lane’s playbook, and the firm will pass quickly. The entry path that works best is through bankers running growth rounds, through portfolio CEO referrals, or through direct outreach to the firm’s partners (Harley Miller, Vinny Pujji, and others), as the firm is reasonably accessible for growth-stage founders with the right metrics. When you pitch, lead with consumer metrics: customer acquisition cost, payback, retention curves, lifetime value, and the path to a category-defining brand position. Left Lane diligence is heavy on unit economics and brand, and partners will dig into cohort data in detail. Caveats: as a focused growth-equity firm, Left Lane’s check is meaningful but the firm typically takes a single board seat per company and is not a platform-style operating partner with a recruiting and marketing bench; governance is growth-equity-standard with board seats, information rights, and a meaningful equity position, and founders should price that in.
Founder reviews
Healthcare AI tools backed by Left Lane Capital
Tools made by companies in Left Lane Capital's portfolio that we cover in the directory.
Portfolio companies in our directory
Other portfolio companies
Companies in Left Lane Capital's portfolio not currently in our directory.
Team
Pitch / review this investor
Have you raised from Left Lane Capital? Founders only — share your honest experience (anonymous OK, moderated before publishing).













